# Study of Oral MRT-2359 in Selected Cancer Patients

Source: https://onco.cc/trials/nct05546268/  
OnCo record `nct05546268` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Oral MRT-2359 in non-small-cell lung cancer, small-cell lung cancer, neuroendocrine tumours, HR-positive / HER2-negative breast cancer and prostate cancer, run by Monte Rosa Therapeutics, Inc, active and no longer recruiting.

## Summary

Study of Oral MRT-2359 in Selected Cancer Patients is a phase 1/2 interventional study registered as NCT05546268 by Monte Rosa Therapeutics, Inc, with 174 participants enrolled, started 2022-10-12 and due to reach its primary completion in 2026-05. Interventions recorded: Oral MRT-2359.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05546268
- Phase: 1/2
- Setting: A Phase 1/2 Study of Oral MRT-2359 in Patients With MYC-Driven and Other Selected Solid Tumors Including Lung Cancer and Diffuse B-Cell Lymphoma
- Sponsor: Monte Rosa Therapeutics, Inc
- Enrolled: 174

## Sources

- ClinicalTrials.gov NCT05546268: https://clinicaltrials.gov/study/NCT05546268

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Prostate cancer](https://onco.cc/cancers/prostate/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- companies: [Monte Rosa Therapeutics](https://onco.cc/companies/monte-rosa/)

---
JSON: https://onco.cc/api/v1/entities/nct05546268.json